Published results showed significant cost savings and decreased cost variability within the first year of implementing a preferred single-vendor program for hip and knee arthroplasty implants.

Joseph A. Bosco III, MD, and colleagues evaluated the use of implants for primary hip and knee arthroplasty from a preferred single-vendor program in the first 12 months of the contract vs. the year prior. Researchers compared per-case implant costs, as well as performance on quality metrics, including 30-day readmission, 30-day surgical site infection and length of stay.